Improvement of blood glucose control in patients with type 2 diabetes
Who takes it
Adults
Adult dose
The recommended dose of this medicine for antidiabetic therapy is 10 mg of dapagliflozin and 100 mg of sitagliptin; the dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs adjustment, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 5/50/500 mg, 5/50/750 mg, or 5/50/1000 mg extended-release tablets should take 2 tablets once daily.
If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be dapagliflozin 10 mg, sitagliptin 100 mg, and the current dose of metformin hydrochloride, or a therapeutically equivalent dose. For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the existing dose of each component.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is adequately controlled (see Precautions for Use, 5. General Precautions).
No dose adjustment is required in patients with mild renal impairment.
If the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided the patient tolerates it well and has no other symptoms that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Improvement of blood glucose control in patients with type 2 diabetes
View approved original textHide original text
This medication is used to help control blood glucose levels in patients with type 2 diabetes. In particular, it assists in conjunction with dietary and exercise therapies when taking dapagliflozin, sitagliptin, and metformin together. This helps effectively manage blood glucose levels. This medication contributes to the prevention of complications by improving blood glucose control.
How to take
Adult dose
The recommended dose of this medicine for antidiabetic therapy is 10 mg of dapagliflozin and 100 mg of sitagliptin; the dose of extended-release metformin hydrochloride is determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding 2000 mg.
To reduce gastrointestinal adverse reactions caused by metformin hydrochloride, take this medicine once daily with a meal, preferably in the evening. If the dose of metformin hydrochloride needs adjustment, adjust it gradually. Patients taking this medicine as 10/100/1000 mg extended-release tablets should take 1 tablet once daily.
Patients taking this medicine as 5/50/500 mg, 5/50/750 mg, or 5/50/1000 mg extended-release tablets should take 2 tablets once daily.
If adequate glycemic control cannot be achieved with combination therapy of metformin hydrochloride and sitagliptin, the starting dose of this medicine should be dapagliflozin 10 mg, sitagliptin 100 mg, and the current dose of metformin hydrochloride, or a therapeutically equivalent dose. For patients switching from combination therapy with dapagliflozin, sitagliptin, and metformin hydrochloride to this medicine, the dose of this medicine should be the existing dose of each component.
The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because changes may cause alterations in glycemic control, any change in treatment for patients with type 2 diabetes should be made under careful monitoring.
To maintain the extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. This medicine may not dissolve completely and may be excreted in the feces. It is not known whether the material excreted in the feces contains the active ingredients of the medicine. If a patient repeatedly reports finding this medicine in the feces, healthcare professionals should assess whether blood glucose is adequately controlled (see Precautions for Use, 5. General Precautions).
No dose adjustment is required in patients with mild renal impairment.
If the estimated glomerular filtration rate (eGFR) is 45 mL/min/1.73m2 or higher and below 60 mL/min/1.73m2, this medicine may be used by adjusting the dose of metformin hydrochloride, one of its components, provided the patient tolerates it well and has no other symptoms that may increase the risk of lactic acidosis.
The starting dose of extended-release metformin hydrochloride is 500mg or 750 mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg.
If the estimated glomerular filtration rate (eGFR) decreases to below 45 mL/min/1.73m2, treatment with this medicine should be discontinued immediately. Renal function should be assessed every 3~6 months.
Precautions
This medication may rarely cause serious allergic reactions due to the sitagliptin component. Therefore, if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck occur within three months after administration, it should be discontinued immediately and consult a doctor.
The medication can cause severe inflammation of the pancreas known as acute pancreatitis. If symptoms such as abdominal pain, vomiting, or nausea occur, you must seek medical attention immediately.
The metformin component in this medication can rarely cause lactic acidosis, which could be life-threatening; if severe fatigue, muscle pain, breathing difficulties, abdominal pain, or hypothermia occur, treatment should be stopped immediately and medical care should be sought.
This medication should not be administered to patients with moderate to severe renal function impairment or acute kidney disease, and patients with decreased kidney function should have regular kidney function tests before and during administration.
Patients with conditions affecting kidney function, such as dehydration, severe infections, heart failure, myocardial infarction, or sepsis should avoid using this medication or use it cautiously.
This medication must be discontinued for a certain period before and after examinations using radiologic iodine contrast agents, and should only be resumed after confirming that kidney function is normal.
This medication should not be used by patients with type 1 diabetes or a history of diabetic ketoacidosis.
The administration of this medication must be temporarily suspended for 48 hours before surgery and until kidney function is restored to normal post-surgery, after which it can be resumed.
In patients with reduced fluid volume or at risk of hypotension, blood pressure reduction and worsening kidney function can occur; hence, fluid status and blood pressure should be monitored periodically.
This medication may increase the risk of genital and urinary tract infections, so treatment should be sought immediately if symptoms of infection occur.
Rarely, this medication may cause severe skin disorders, joint pain, or blistering skin conditions. Consult a doctor if skin rashes or severe joint pain occur.
During the use of this medication, be vigilant for symptoms of hypoglycemia, especially when used in combination with other hypoglycemic agents, as this may increase the risk of low blood sugar.
Alcohol consumption may increase the risk of lactic acidosis; therefore, excessive alcohol should be avoided while taking this medication.
Long-term use of this medication may result in vitamin B12 deficiency, so it is advisable to monitor vitamin B12 levels with regular blood tests.
Pregnant women or those with placental function issues should not use this medication, and must consult a doctor if planning to become pregnant or if already pregnant.
Side effects
Severe hypersensitivity reaction
anaphylaxis
angioedema
Stevens-Johnson syndrome
acute pancreatitis
hemorrhagic pancreatitis
necrotizing pancreatitis
lactic acidosis
hypoglycemia
vulvovaginitis
Show 204 moreCollapse
balanitis
genital infection
urinary tract infection
fungal infection
perineal necrosis
decreased fluid volume
thirst
diabetic ketoacidosis
dizziness
constipation
dry mouth
back pain
dysuria
polyuria
nocturia
interstitial nephritis
elevated hematocrit
decreased serum creatinine clearance
dyslipidemia
elevated serum creatinine
elevated blood urea
weight loss
rash
urosepsis
pyelonephritis
acute kidney injury
renal dysfunction
gastroesophageal reflux disease
epigastric pain
diverticulosis
bowel perforation
chronic pancreatitis
hyperglycemia
paresthesia
cerebral infarction
nerve compression
sinusitis
diverticulitis
pelvic inflammatory disease
pneumonia
pulmonary tuberculosis
asthenia
pain
ligament sprain
road traffic accident
drug overdose
ankle fracture
hand fracture
pelvic fracture
meniscus injury
thoracic vertebra fracture
tibia fracture
keratitis
chronic obstructive pulmonary disease
hemoptysis
cerebral hemorrhage
peripheral artery occlusion
angina pectoris
myocardial infarction
depression
suicide attempt
gastric adenocarcinoma
anaphylactic reaction
acute pyelonephritis
chest pain
dyspepsia
nausea
diarrhea
vomiting
gastritis
headache
urinary retention
increased alanine aminotransferase
increased aspartate aminotransferase
decreased appetite
dysgeusia
palpitations
insomnia
fatty liver
gallbladder polyp
tinnitus
taste disturbance
erythema
pruritus
urticaria
rash
dysgeusia
drowsiness
tension headache
carpal tunnel syndrome
diabetic neuropathy
coma
neuralgia
peripheral neuropathy
sleep disorders
syncope
tremor
bronchitis
shingles
herpes simplex
stye
joint abscess
laryngitis
otitis media
periodontal abscess
rhinitis
onychomycosis
edema
fever
facial edema
facial pain
warmth
flu-like symptoms
vaginal discharge
menstrual irregularities
pruritus
arthralgia
musculoskeletal pain
limb pain
muscle weakness
myalgia
osteoarthritis
ligament sprain
diabetic retinopathy
cough
dyspnea
orthostatic hypotension
anxiety disorder
nocturnal enuresis
elevated blood lactate
lymphocytopenia
elevated serum triglycerides
increased low-density lipoprotein
hyperglycemia
thrombocytopenia
vesicular bullous pemphigoid
myalgia
limb pain
back pain
interstitial lung disease
sweating
coin-like eczema
eczema
hyperkeratosis
skin lesion
flank pain
muscle fiber pain
limb discomfort
muscle cramp
musculoskeletal discomfort
osteoporosis
contusion
orbital fracture
foot fracture
gastrointestinal foreign body
laceration
ligament rupture
skin abrasion
tendon rupture
dry eyes
eye pain
retinal disorders
visual impairment
blepharitis
cataract
conjunctival edema
allergic conjunctivitis
conjunctivitis
diplopia
eyelid edema
keratitis
ocular hypertension
visual impairment
vitreous floaters
oropharyngeal pain
allergic rhinitis
asthma
vocal cord dysfunction
epistaxis
sleep apnea syndrome
wheezing
atherosclerosis
flushing
peripheral coldness
varicose veins
vascular headache
angina pectoris
atrial fibrillation
diastolic dysfunction
anxiety disorder
auditory hallucinations
suicide attempt
bile duct stones
cholangitis
liver cyst
dizziness
anal genital warts
gastric adenoma
neuroma
male reproductive hormone deficiency
thyroid cyst
thyroid nodule
food allergy
erythrocytosis
Not everyone experiences these, and they can vary from person to person.
Storage
Store this medication in a tightly closed container to prevent exposure to air or moisture. It is crucial to maintain storage temperatures between 1 degree and 30 degrees Celsius. This way, the efficacy of the medication can be safely preserved.
Appearance and packaging
Appearance
Pink oval extended-release film-coated tablet
Package unit
30 tablets/bottle
Same-ingredient medicines
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety. Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.